When a Painful Rash Keeps Recurring: A Case of Seronegative Amyopathic Dermatomyositis Without Neurological Sequelae

Ahmed Harazeen1, Brian Walter2, Xiangping Li1

  • 1Neurology, University of Texas Medical Branch, Galveston, USA.

Cureus
|September 1, 2023
PubMed

Insights

Seronegative amyopathic dermatomyositis (SADM) presents with painful skin rashes and requires monitoring for neurological issues and cancer. Early diagnosis and multidisciplinary care are crucial for managing this rare autoimmune condition.

Area of Science:

  • Dermatology
  • Rheumatology
  • Autoimmune Diseases

Background:

  • Seronegative amyopathic dermatomyositis (SADM) is a rare autoimmune subtype of dermatomyositis (DM) affecting skin and muscles.
  • Its etiology involves complex genetic, environmental, and immunological interactions.
  • Diagnosis relies on clinical findings, biopsies, and exclusion of specific antibodies.

Observation:

  • A 30-year-old female experienced recurrent, painful erythematous rashes on her face and hands, alongside joint pain.
  • Skin biopsy revealed changes suggestive of DM, but myositis panels, EMG, and MRI were normal.
  • Reduced C3 and C4 complement levels were noted.

Findings:

  • The patient was diagnosed with SADM based on clinical presentation and biopsy, despite negative serology for myositis.
  • Treatment with methotrexate, hydroxychloroquine, and prednisone led to significant improvement in skin manifestations within a year.
  • This case underscores the diagnostic challenges of SADM, particularly its seronegative variant.

Implications:

  • SADM should be considered in patients with unexplained, painful skin rashes.
  • Close monitoring for neurological complications and malignancy is essential due to potential delayed onset.
  • A multidisciplinary approach is recommended for optimal management of SADM patients.

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
990
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
12
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.9K